Visgeneer (TWO:4197) — Market Cap & Net Worth
Market Cap & Net Worth: Visgeneer (4197)
Visgeneer (TWO:4197) has a market capitalization of $8.79 Million (NT$278.87 Million) as of September 17, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #27482 globally and #1585 in its home market, demonstrating a -7.51% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Visgeneer's stock price NT$9.24 by its total outstanding shares 30181000 (30.18 Million). Also see 4197 total assets for a full breakdown of the balance sheet.
Visgeneer Market Cap History: 2015 to 2026
Visgeneer's market capitalization history from 2015 to 2026. Data shows change from $26.63 Million to $8.79 Million (-6.90% CAGR). Also see Visgeneer (4197) cash conversion ratio for how efficiently the company converts equity into cash flow.
Visgeneer Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Visgeneer's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 4197 live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.05x
Visgeneer's market cap is 0.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.76x
Visgeneer's market cap is 1.76 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $12.40 Million | $163.01 Million | $381.00K | 0.08x | 32.54x |
| 2017 | $12.73 Million | $157.61 Million | -$30.66 Million | 0.08x | N/A |
| 2018 | $9.98 Million | $142.54 Million | -$31.89 Million | 0.07x | N/A |
| 2019 | $12.79 Million | $151.99 Million | -$31.75 Million | 0.08x | N/A |
| 2020 | $13.50 Million | $175.96 Million | $603.00K | 0.08x | 22.39x |
| 2021 | $12.17 Million | $165.29 Million | $820.00K | 0.07x | 14.84x |
| 2022 | $10.27 Million | $157.96 Million | $12.35 Million | 0.07x | 0.83x |
| 2023 | $9.98 Million | $147.99 Million | -$19.59 Million | 0.07x | N/A |
| 2024 | $9.29 Million | $115.76 Million | -$17.73 Million | 0.08x | N/A |
| 2025 | $9.22 Million | $179.06 Million | $5.25 Million | 0.05x | 1.76x |
Competitor Companies of 4197 by Market Capitalization
Companies near Visgeneer in the global market cap rankings as of September 17, 2026. Review Visgeneer tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Visgeneer by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Visgeneer Historical Marketcap From 2015 to 2026
Between 2015 and today, Visgeneer's market cap moved from $26.63 Million to $ 8.79 Million, with a yearly change of -6.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$8.79 Million | -4.74% |
| 2025 | NT$9.22 Million | -0.72% |
| 2024 | NT$9.29 Million | -6.95% |
| 2023 | NT$9.98 Million | -2.78% |
| 2022 | NT$10.27 Million | -15.62% |
| 2021 | NT$12.17 Million | -9.86% |
| 2020 | NT$13.50 Million | +5.58% |
| 2019 | NT$12.79 Million | +28.10% |
| 2018 | NT$9.98 Million | -21.58% |
| 2017 | NT$12.73 Million | +2.68% |
| 2016 | NT$12.40 Million | -53.44% |
| 2015 | NT$26.63 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Visgeneer was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.79 Million USD |
| MoneyControl | $8.79 Million USD |
| MarketWatch | $8.79 Million USD |
| marketcap.company | $8.79 Million USD |
| Reuters | $8.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Visgeneer
Visgeneer Inc. engages in the provision of health solutions in the fields of medical device, cosmetics and skin care, Zeaxanthin, and cancer gene diagnostics in Europe and Asia. The company offers blood glucose and ketone, uric acid, and cholesterol monitoring systems. It also provides functional masks, such as wood pulp mask, invisible mask, black mask, pure cloth mask, and bio cellulose mask; f… Read more